Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
VFEND Voriconazole Aspergillosis, Invasive Withdrawn
VFEND Voriconazole Aspergillosis, Invasive List with clinical criteria and/or conditions Complete
VFEND Voriconazole Candidemia List with clinical criteria and/or conditions Complete
Viacoram perindopril arginine / amlodipine Hypertension, essential Reimburse with clinical criteria and/or conditions Complete
Viberzi eluxadoline Irritable bowel syndrome with diarrhea Do not reimburse Complete
Victoza liraglutide Diabetes Mellitus, Type 2 (pediatric) Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. Not filed
Victoza Liraglutide Diabetes mellitus, Type 2 Do not list Complete
Victoza Liraglutide Diabetes Mellitus, Type 2 Withdrawn
Victrelis Boceprevir Hepatitis C, chronic List with clinical criteria and/or conditions Complete
Victrelis Boceprevir Hepatitis C, chronic List with criteria/condition Complete